ALKBH5 and ovarian carcinoma: ALKBH5 was also suggested to contribute to resistance to PARP inhibitors in BRCA1/2-mutated ovarian cancer cell lines by regulating the expression of FZD10 mRNA and mediating the Wnt signaling pathway [14].